Using our model of Lmo2-transgenic T-ALL, we have shown that Dynole 34-2 enhanced the efficacy of chemotherapy, independently of the presence of collaborative mutations of signalling pathways in the primary leukemias tested, suggesting that multiple fundamental processes regulated by DDE are essential for LSCs. The gene discussed is LMO2; the disease is acute lymphoblastic leukemia.